Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies

BACKGROUND: RAS/RAF/MAPK activation (mutational or non-mutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane binding pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Badar, Talha, Cortes, Jorge E, Ravandi, Farhad, O’Brien, Susan, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Borthakur, Gautam
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4509631/
https://ncbi.nlm.nih.gov/pubmed/25795639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.02.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados